AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9523247
Drug: Low-level exposure
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level exposure (MA + PGA < or = 159 mg/g creatinine)
Trial: 9523247
Drug: High-level exposure
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-level exposure (MA + PGA > 159 mg/g creatinine)
Trial: 8595636
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil suspension 30 mg/kg per day in two divided doses (n = 235)
Trial: 8595636
Drug: Amoxicillin/clavulanate suspension
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate suspension 40 mg/kg per day in three divided doses (n = 242)
Trial: 8595636
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil suspension (bacteriologically assessable patients)
Trial: 8595636
Drug: Amoxicillin/clavulanate suspension
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate suspension (bacteriologically assessable patients)
Trial: 8595636
Drug: Amoxicillin/clavulanate suspension
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate suspension
Trial: 24730013
Drug: BIS not
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS not visible (BIS hidden, monitoring based on clinical signs and expiratory fraction of halogenated anesthetic agents)
Trial: 7811176
Drug: Metaproterenol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol (80 mg/day)
Trial: 2349369
Drug: Caffeine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (single dose equivalent to two to four cups of coffee)
Trial: 7273596
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg brotizolam
Trial: 7273596
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg brotizolam
Trial: 7273596
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg flurazepam
Trial: 31067587
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy by PTs with varying experience (2 to 21 years)
Trial: 17614893
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of didactic guidelines and netiquette advice
Trial: 11351930
Drug: Intramuscular buprenorphine/naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular buprenorphine/naloxone (1/0.25, 2/0.5, 4/1, 8/2, 16/4 mg)
Trial: 11351930
Drug: Intramuscular hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular hydromorphone (10 mg) and naloxone (0.25 mg)
Trial: 11351930
Drug: Intramuscular buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular buprenorphine alone (8 mg)
Trial: 11351930
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine alone (8 mg)
Trial: 9135734
Drug: pCMV‐CFTR:2.4 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pCMV‐CFTR:2.4 mg DOTAP (400 micrograms)
Trial: 2823594
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of psyllium gum and wheat bran
Trial: 2823594
Drug: Control (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (4 g/d fiber)
Trial: 29859267
Drug: TeleCAM (home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TeleCAM (home-based telerehabilitation intervention using pre-loaded tablets and IVR system technology)
Trial: 27662565
Drug: Daily sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sedation interruption + protocolized sedation
Trial: 27662565
Drug: Daily sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sedation interruption + protocolized sedation (for children > 4 years old)
Trial: 22288788
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy group (n = 14)
Trial: 17697398
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g short-chain fructo-oligosaccharides (sc-FOS) per day for 6 weeks
Trial: 17697398
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g placebo (sucrose and maltodextrins) per day for 6 weeks
Trial: 10635157
Drug: Mini-transitional implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-transitional implants (MTIs) placed medially to the permanent implants.
Trial: 8544287
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of fentanyl and midazolam with 67 % N2O
Trial: 8544287
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of fentanyl and midazolam without N2O
Trial: 22664648
Drug: Medtable™ EMR-integrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medtable™ EMR-integrated tool for medication management
Trial: 14583064
Drug: Sibutramine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (10-20 mg daily)
Trial: 1284156
Drug: Gallopamil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil (50 mg t.i.d. for 4 weeks)
Trial: 6377491
Drug: Orgotein 16
RxNorm normalized name: Orgotein
DrugBank: Orgotein (DB11444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orgotein 16 mg
Trial: 6377491
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate 40 mg
Trial: 6377491
Drug: Orgotein 8
RxNorm normalized name: Orgotein
DrugBank: Orgotein (DB11444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orgotein 8 mg
Trial: 26695494
Drug: Nonpsychotropic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpsychotropic medications
Trial: 21308265
Drug: Standard anxiolytics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anxiolytics (benzodiazepines, buspirone, antidepressants)
Trial: 12378657
Drug: Crystalloid intravenous
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid intravenous fluid
Trial: 12378657
Drug: Colloid intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid intravenous fluid
Trial: 9988284
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors for left ventricular dysfunction (LVD) and/or diabetes mellitus (DM)
Trial: 9988284
Drug: Aspirin for
RxNorm normalized name: Aspirin 81 MG Oral Tablet, Chewable [ASPIRIN FOR CHILDREN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin for history of myocardial infarction (MI)
Trial: 9988284
Drug: Warfarin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin for chronic atrial fibrillation (AF)
Trial: 9988284
Drug: Any or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any or all indicated medications
Trial: 1967677
Drug: Intramuscular hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular hydrocortisone (200 mg)
Trial: 1967677
Drug: Rectal hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal hydrocortisone (200 mg)
Trial: 7375869
Drug: Biarison (600-900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biarison (600-900 mg daily)
Trial: 7375869
Drug: Indomethacin (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50-100 mg daily)
Trial: 7375869
Drug: Biarison (used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biarison (used in treatment of active SLE)
Trial: 30461337
Drug: Dienogest 2
RxNorm normalized name: dienogest 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest 2 mg once daily
Trial: 20204674
Drug: Raltitrexed (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed (3 mg/m² i.v. every 21 days) plus gefitinib (250 mg p.o. daily)
Trial: 20204674
Drug: Raltitrexed (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed (3 mg/m² i.v. every 21 days)
Trial: 18809275
Drug: L-carnitine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (0.5 g/day for two days, followed by 1g/day for two days, and then 2g/day for 10 days)
Trial: 18809275
Drug: L-carnitine (during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (during exploratory analysis)
Trial: 10848879
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (6 U/m2/day) with low dose ethinyl oestradiol, administered either once daily (OD) or twice daily (BID)
Trial: 10848879
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (6 U/m2/day) with low dose ethinyl oestradiol
Trial: 29460811
Drug: Viscosity-regulating pectin
RxNorm normalized name: Pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscosity-regulating pectin solution (VREF group, n = 15)
Trial: 29460811
Drug: Conventional enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional enteral nutrition administration (Control group, n = 12)
Trial: 26764413
Drug: ivabradine 2×7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 2×7.5 mg
Trial: 25018120
Drug: Inactivated poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliovirus vaccine (IPV) 0.5 mL intramuscularly (containing 40, 8, and 32 D antigen units for serotypes 1, 2, and 3)
Trial: 19446951
Drug: Cizolirtine citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cizolirtine citrate 800 mg/d
Trial: 19446951
Drug: Oxybutynin 15
RxNorm normalized name: oxyBUTYnin 15 mg/24 hr oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 15 mg/d
Trial: 15640476
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (25 mg Zn daily)
Trial: 12195349
Drug: Saquinavir in
RxNorm normalized name: Product containing saquinavir in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir in combination with either ritonavir or nelfinavir, plus delavirdine, adefovir, or both; duration: 48 weeks
Trial: 11551136
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment after neoadjuvant chemotherapy
Trial: 9923574
Drug: Tacrine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine treatment with serum concentrations above 7 ng/ml
Trial: 9923574
Drug: Tacrine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine treatment with serum concentrations below 7 ng/ml
Trial: 9923574
Drug: Tacrine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine treatment with serum concentrations above 5 ng/ml
Trial: 9923574
Drug: Tacrine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine treatment with serum concentrations above 9 ng/ml
Trial: 7014073
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg morphine
Trial: 3073322
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg new analgesic
Trial: 3073322
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg new analgesic
Trial: 22595934
Drug: 0.005% latanoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005% latanoprost ophthalmic solution
Trial: 16216827
Drug: ghrelin 40
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ghrelin 40 mug administered intravenously over 30 minutes
Trial: 16216827
Drug: saline administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline administered intravenously over 30 minutes
Trial: 12665160
Drug: Grippostad-C (acetaminophen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grippostad-C (acetaminophen, caffeine, chlorpheniramine, ascorbic acid)
Trial: 12665160
Drug: Acetaminophen, caffeine,
RxNorm normalized name: Acetaminophen, Caffeine, and Dihydrocodeine Bitartrate Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen, caffeine, ascorbic acid (reference 2)
Trial: 9461937
Drug: Tenoxicam 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 40 mg rectally followed by 20 mg daily for 7 days
Trial: 9461937
Drug: Piroxicam 40
RxNorm normalized name: piroxicam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 40 mg rectally followed by 20 mg daily for 7 days
Trial: 27101675
Drug: CPAP combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP combined with modified oral appliance (MOA)
Trial: 23746205
Drug: Dried purple
RxNorm normalized name: peptone,dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried purple carrot (118.5 mg/day of anthocyanins and 259.2 mg/day of phenolic acids for 4 weeks)
Trial: 16737761
Drug: Glutamate infusion
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate infusion during 1h immediately after skin closure
Trial: 16737761
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion during 1h immediately after skin closure
Trial: 3317180
Drug: 100 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/kg of epsilon‐aminocaproic acid (EACA), orally every 4 hours for 5 days (maximum 30 g/day)
Trial: 29579763
Drug: Individualised homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised homeopathic medicine
Trial: 16020212
Drug: ALA-IPL treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-IPL treatment
Trial: 10540045
Drug: OBTM (Omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBTM (Omeprazole 20 mg b.d., Bismuth 120 mg q.d.s., Tetracycline 500 mg q.d.s., Metronidazole 250 mg q.d.s.)
Trial: 10540045
Drug: RbcTM (Ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RbcTM (Ranitidine bismuth citrate 400 mg b.d., Tetracycline 500 mg q.d.s., Metronidazole 250 mg q.d.s.)
Trial: 8905425
Drug: Intravenous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous octreotide (100 micrograms three times daily for 10 days)
Trial: 8905425
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no octreotide treatment)
Trial: 9391254
Drug: Intravenous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous octreotide
Trial: 1804603
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Aspirin (50 mg/day)
Trial: 6136132
Drug: H1 +
RxNorm normalized name: Histamine H1 Receptor Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 + H2-antagonists (Chlorpheniramine 4 X 4 mg/d and Cimetidine 4 X 400 mg/d for 4 weeks)
Trial: 6136132
Drug: H1-antagonist alone
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H1-antagonist alone (Chlorpheniramine 4 X 4 mg/d for 4 weeks)
Trial: 6136132
Drug: H1 +
RxNorm normalized name: Histamine H1 Receptor Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 + H2-antagonists (Chlorpheniramine and Cimetidine for 4 weeks)
Trial: 6136132
Drug: H1-antagonist (Chlorpheniramine)
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H1-antagonist (Chlorpheniramine)
Trial: 6136132
Drug: H1 +
RxNorm normalized name: Histamine H1 Receptor Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 + H2-antagonists
Trial: 26072396
Drug: Pretreatment screening
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment screening for TPMT variants with dose reduction (50% for heterozygous carriers, 0%-10% for homozygous carriers)
Trial: 10861154
Drug: Posterior lumbar
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior lumbar plexus block with 0.4 ml/kg bupivacaine, 0.5%, with epinephrine
Trial: 8477964
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (13 to 15 mg/kg/day)
Trial: 31931848
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin 10 mg/kg once daily for 3 days
Trial: 30148871
Drug: Time-averaged albuminuria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-averaged albuminuria cut-off of 900 mg/day
Trial: 24131075
Drug: CP 3
RxNorm normalized name: Pseudoephed/Acetaminop/Dpha/Cp 30 mg-500 mg-25 mg-2 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP 3 g (Group B)
Trial: 24131075
Drug: CP 3
RxNorm normalized name: Pseudoephed/Acetaminop/Dpha/Cp 30 mg-500 mg-25 mg-2 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP 3 g and vitamin C 500 mg (Group C)
Trial: 24131075
Drug: No supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplement (Group A)
Trial: 24131075
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 500 mg (Group D)
Trial: 18407003
Drug: Web-based smoking-cessation
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Web-based smoking-cessation program plus nicotine patch
Trial: 12428224
Drug: Oral pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pulse prednisolone, methotrexate, plus sulfasalazine
Trial: 1924640
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg alprazolam four times daily
Trial: 1924640
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg fluoxetine every morning
Trial: 1924640
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg alprazolam four times daily and 60 mg fluoxetine every morning
Trial: 7043341
Drug: PGE2 gel
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 gel (2 ml containing 0.5 mg PGE2)
Trial: 7043341
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (gel without PGE2)
Trial: 7043341
Drug: PGE2 gel
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 gel (0.5 mg) in subsequent open study
Trial: 29229898
Drug: Hepabulin (10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepabulin (10,000 units) intravenously injected intraoperatively, daily for 1 week, weekly for 1 month, and then once per month
Trial: 25440110
Drug: Infusions prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions prepared from 2 g of C citratus leaf powder once daily for 30 days
Trial: 25440110
Drug: Infusions prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions prepared from 4 g of C citratus leaf powder once daily for 30 days
Trial: 25440110
Drug: Infusions prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions prepared from 8 g of C citratus leaf powder once daily for 30 days
Trial: 21060071
Drug: Omega-3-acid ethyl
RxNorm normalized name: Omega-3-Acid Ethyl Esters
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3-acid ethyl esters-90 (1 g/d for 1 year)
Trial: 7512433
Drug: Methylprednisolone 125
RxNorm normalized name: methylprednisolone 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 125 mg
Trial: 16416000
Drug: Bicyclo tablets
RxNorm normalized name: alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
DrugBank: Biperiden (DB00810)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicyclo tablets
Trial: 12549799
Drug: Bifidobacteria Bb12
RxNorm normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacteria Bb12 supplement
Trial: 12549799
Drug: Bifidobacteria Bb12
RxNorm normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacteria Bb12 and Streptococcus thermophilus supplement
Trial: 12549799
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula without supplement (Control)
Trial: 9625220
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg caffeine